CVR number 30490444
Industry 32.5000 Manufacture of medical and dental instruments and supplies

HR2ORTOPÆDI ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Bankruptcy risk for industry  2.2% 2.2% 2.2% 2.2% 2.2%  
Bankruptcy risk  2.3% 1.8% 1.9% 2.5% 3.4%  
Credit score (0-100)  64 69 69 61 54  
Credit rating  BBB A A BBB BBB  
Credit limit (kDKK)  0.1 1.7 0.8 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales  0 0 0 0 0  
Gross profit  2,764 3,387 3,093 2,519 3,849  
EBITDA  300 1,023 918 666 1,791  
EBIT  169 899 795 542 1,675  
Pre-tax profit (PTP)  131.5 871.6 776.6 533.8 1,702.4  
Net earnings  96.5 671.9 600.0 414.3 1,322.7  
Pre-tax profit without non-rec. items  132 872 777 534 1,702  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Tangible assets total  522 418 295 171 125  
Shareholders equity total  2,078 2,750 2,100 2,014 1,837  
Interest-bearing liabilities  1,651 133 328 5.5 0.0  
Balance sheet total (assets)  5,004 4,199 3,265 2,844 3,057  
Net Debt  -2,007 -1,645 -1,106 -1,802 -945  
 
See the entire balance sheet

Volume 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,764 3,387 3,093 2,519 3,849  
Gross profit growth  -16.1% 22.6% -8.7% -18.6% 52.8%  
Employees  4 4 4 3 3  
Employee growth %  0.0% 0.0% 0.0% -25.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  5,004 4,199 3,265 2,844 3,057  
Balance sheet change%  8.4% -16.1% -22.2% -12.9% 7.5%  
Added value  299.6 1,023.1 918.2 666.1 1,791.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -261 -227 -247 -247 -163  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  6.1% 26.6% 25.7% 21.5% 43.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.5% 19.6% 21.3% 17.8% 57.8%  
ROI %  4.7% 27.0% 29.7% 24.3% 88.4%  
ROE %  3.6% 27.8% 24.7% 20.1% 68.7%  

Solidity 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Equity ratio %  41.6% 65.5% 64.3% 70.8% 60.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -669.9% -160.8% -120.5% -270.5% -52.8%  
Gearing %  79.5% 4.8% 15.6% 0.3% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  4.2% 3.1% 7.8% 5.3% 87.4%  

Liquidity 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Quick Ratio  1.4 2.4 2.3 2.8 2.4  
Current Ratio  1.5 2.5 2.4 2.9 2.4  
Cash and cash equivalent  3,658.0 1,777.8 1,434.1 1,807.7 945.1  

Capital use efficiency 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,363.3 2,130.5 1,593.1 1,607.0 1,666.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/8
2021
2021/8
2022
2022/8
2023
2023/8
2024
2024/8
Net sales / employee  0 0 0 0 0  
Added value / employee  75 256 230 222 597  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  75 256 230 222 597  
EBIT / employee  42 225 199 181 558  
Net earnings / employee  24 168 150 138 441